Tandem Diabetes Care has demonstrated a notable turnaround in operating income, shifting from significant losses to modest profitability by 2025, driven by expanded product adoption and technology integration. However, net losses persist due to elevated R&D and SG&A spending amid a strategic pivot in U.S. reimbursement from upfront pump sales under a durable medical equipment model to a pay-as-you-go pharmacy benefit model. The company’s competitive moat relies heavily on its Control-IQ+ insulin delivery system integrated with continuous glucose monitoring and a digital health ecosystem, yet faces growing pressure from larger rivals and reimbursement uncertainties. Capital allocation favors sustained R&D investment over shareholder returns, reflecting the need to innovate in a complex regulatory and market environment.